NEWS
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
HOOKIPA Pharma announced updated Phase 2 clinical data for HB-200 combined with pembrolizumab in treating recurrent/metastatic HPV16+ head and neck cancer at the ASCO 2024 Annual Meeting. Out of 35 evaluable patients, results showed a 37% confirmed objective response rate (ORR), 11% complete response (CR) rate, and 69% disease control rate (DCR). Notably, in a subset of 17 patients with a PD-L1 CPS of 20 or higher, the ORR was 53%, CR rate 18%, and DCR 82%. Preliminary progression-free survival (PFS) for this subset was 16.3 months, with a 9-month overall survival (OS) rate of 88%. The treatment was generally well-tolerated, with Grade ≥3 treatment-related adverse events reported in 15% of patients. The pivotal Phase 2/3 trial is set to begin in Q4 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1064Followers
65Following
7219Visitors
Follow